Karbagen

Oxcarbazepine, the active ingredient in Karbagen, is a sodium channel blocker presented as an oral formulation for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures and other epilepsy syndromes. By stabilizing hyperexcited neuronal membranes, it reduces repetitive neuronal firing and helps control seizure activity.

GNH USA supplies Karbagen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for patient care and supporting healthcare providers in diverse markets.

Oxcarbazepine is used in the management of seizure disorders by modulating neuronal excitability. - Partial seizures: reduces the frequency and severity of focal onset seizures, improving daily functioning in patients with epilepsy. - Generalized tonic‑clonic seizures: helps control convulsive episodes in generalized epilepsy, decreasing the risk of injury and improving quality of life. - Epilepsy (overall): serves as adjunctive therapy to enhance overall seizure control across multiple epilepsy syndromes when monotherapy is insufficient.

Oxcarbazepine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness that may affect balance. - Drowsiness: increased sleepiness or fatigue, especially after dose initiation. - Nausea: mild gastrointestinal upset, often transient during early treatment. - Headache: transient cranial pain that may vary in intensity. - Double vision: occasional blurred or duplicated images, usually resolving with continued therapy.

Serious or Rare Side Effects: - Hyponatremia: low blood sodium that can cause confusion, seizures, or coma if severe. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis, requiring immediate medical attention. - Hepatic dysfunction: elevated liver enzymes, hepatitis, or potential liver failure in rare cases.

When prescribing oxcarbazepine, clinicians should consider several safety precautions to minimize risks. - Renal function: adjust dose in patients with impaired renal clearance. - Hepatic function: monitor liver enzymes in patients with existing liver disease. - Electrolytes: check serum sodium regularly, especially in the elderly. - Mood changes: observe for signs of depression or suicidal thoughts. - Drug interactions: review concomitant medications that affect sodium channels or metabolism. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Oxcarbazepine can affect the plasma levels of several co‑administered drugs, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: may cause severe toxicity due to additive sodium channel blockade. - Anticonvulsant enzyme inducers (e.g., phenytoin, phenobarbital): can markedly reduce oxcarbazepine effectiveness. - Certain antidepressants (e.g., tricyclics): increased risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy, requiring alternative contraception. - NSAIDs: can increase risk of hyponatremia. - ACE inhibitors or diuretics: may potentiate sodium loss and hyponatremia.